News Releases

Date Title
12/05/17
Summary ToggleHeron Therapeutics Announces Pricing of Public Offering of Common Stock Printer Friendly Version
12/04/17
Summary ToggleHeron Therapeutics Announces Public Offering of Common Stock Printer Friendly Version
11/09/17
Summary ToggleHeron Therapeutics Announces U.S. FDA Approval of CINVANTI™ (aprepitant) Injectable Emulsion for the Prevention of Acute and Delayed Chemotherapy-Induced Nausea and Vomiting (CINV) Printer Friendly Version
11/08/17
Summary ToggleHeron Therapeutics to Present at the Jefferies London Healthcare Conference Printer Friendly Version
11/06/17
Summary ToggleHeron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress Printer Friendly Version
10/26/17
Summary ToggleHeron Therapeutics Granted FDA Fast Track Designation for HTX-011 to Reduce Postoperative Pain and the Need for Opioid Analgesics for 72 Hours Printer Friendly Version
09/18/17
Summary ToggleHeron Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Printer Friendly Version
08/09/17
Summary ToggleHeron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress Printer Friendly Version
08/09/17
Summary ToggleHeron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDA Printer Friendly Version
05/30/17
Summary ToggleHeron Therapeutics to Present at the Jefferies 2017 Healthcare Conference Printer Friendly Version
05/10/17
Summary ToggleHeron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress Printer Friendly Version
05/09/17
Summary ToggleHeron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare Conference Printer Friendly Version
04/24/17
Summary ToggleHeron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, Finance Printer Friendly Version
03/28/17
Summary ToggleHeron Therapeutics to Present at the 16th Annual Needham Healthcare Conference Printer Friendly Version
03/13/17
Summary ToggleHeron Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference Printer Friendly Version
02/28/17
Summary ToggleHeron Therapeutics to Present at the 37th Annual Cowen and Company Healthcare Conference Printer Friendly Version
02/24/17
Summary ToggleHeron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis Guidelines Printer Friendly Version
02/23/17
Summary ToggleHeron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Progress Printer Friendly Version
02/08/17
Summary ToggleHeron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference Printer Friendly Version
01/31/17
Summary ToggleHeron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional Shares Printer Friendly Version
01/19/17
Summary ToggleHeron Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock Printer Friendly Version
01/18/17
Summary ToggleHeron Therapeutics Announces Proposed Public Offering of Common Stock Printer Friendly Version
01/12/17
Summary ToggleHeron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Printer Friendly Version
01/05/17
Summary ToggleHeron Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference Printer Friendly Version
01/04/17
Summary ToggleHeron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies Printer Friendly Version
01/04/17
Summary ToggleHeron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty Printer Friendly Version